SCHEMBL23623296

SCHEMBL23623296

COc1ccc(C(C)(C)C)cc1-c1cc(CNC(=O)c2ccccc2OC(F)F)n[nH]1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 5/20 0.40
POLB P06746 2/20 0.40
HPGD P15428 5/20 0.40
MAPT P10636 4/20 0.40
NPSR1 Q6W5P4 3/20 0.40
TP53 P04637 2/20 0.40
GLA P06280 1/20 0.40
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPK1 P28482 2/20 0.38
BTK Q06187 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23623348 0.89 ALDH1A1 (0.46) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL23623812 0.89 HPGD (0.46) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL23623546 0.87 SMN1; SMN2 (0.41) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL23623561 0.84 TP53 (0.46) ALDH1A1POLBHPGDMAPTNPSR1
SCHEMBL24177602 0.82 POLB (0.47) ALDH1A1POLBHPGDMAPTTP53
SCHEMBL23623644 0.82 KCNK3 (0.45) ALDH1A1POLBHPGDMAPTNPSR1
SCHEMBL23623252 0.80 TSHR (0.43) MEN1KMT2APOLBHPGDMAPT
SCHEMBL23623650 0.80 SMN1; SMN2 (0.43) MEN1KMT2AALDH1A1POLBMAPT
SCHEMBL31461719 0.80 HDAC3 (0.47) ALDH1A1POLBHPGDMAPTKDM4E
SCHEMBL23623291 0.79 KMT2A (0.43) MEN1KMT2AALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091590-A1 COMPOUNDS FOR USE IN TREATING GASTRIC CANCER BERG LLC (US) 2023-05-25 WO disclosed
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2022-01-06 US disclosed
US-11091447-B2 UBE2K modulators and methods for their use BERG LLC (US) 2021-08-17 US disclosed
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2021-07-15 US disclosed
WO-2021138540-A1 POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER BERG LLC (US) 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091447-B2 UBE2K modulators and methods for their use UBE2N, UBE2B, UBE2E1 MEN1 4260/4885KMT2A 1523/4885ALDH1A1 1803/4885
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 MEN1 4260/4885KMT2A 1523/4885ALDH1A1 1803/4885
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 MEN1 4260/4885KMT2A 1523/4885ALDH1A1 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.